A cGAS-dependent response links DNA damage and senescence in alveolar epithelial cells: a potential drug target in IPF.


Journal

American journal of physiology. Lung cellular and molecular physiology
ISSN: 1522-1504
Titre abrégé: Am J Physiol Lung Cell Mol Physiol
Pays: United States
ID NLM: 100901229

Informations de publication

Date de publication:
01 11 2021
Historique:
pubmed: 16 9 2021
medline: 11 11 2021
entrez: 15 9 2021
Statut: ppublish

Résumé

Alveolar epithelial cell (AEC) senescence is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Mitochondrial dysfunction including release of mitochondrial DNA (mtDNA) is a feature of senescence, which led us to investigate the role of the DNA-sensing guanine monophosphate-adenine monophosphate (GMP-AMP) synthase (cGAS) in IPF, with a focus on AEC senescence. cGAS expression in fibrotic tissue from lungs of patients with IPF was detected within cells immunoreactive for epithelial cell adhesion molecule (EpCAM) and p21, epithelial and senescence markers, respectively. Submerged primary cultures of AECs isolated from lung tissue of patients with IPF (IPF-AECs,

Identifiants

pubmed: 34524912
doi: 10.1152/ajplung.00574.2020
doi:

Substances chimiques

Benzofurans 0
CDKN1A protein, human 0
Cyclin-Dependent Kinase Inhibitor p21 0
Cytokines 0
DNA, Mitochondrial 0
EPCAM protein, human 0
Epithelial Cell Adhesion Molecule 0
RNA, Small Interfering 0
RU.521 0
Etoposide 6PLQ3CP4P3
Nucleotidyltransferases EC 2.7.7.-
cGAS protein, human EC 2.7.7.-
Deoxyribonuclease I EC 3.1.21.1

Banques de données

figshare
['10.6084/m9.figshare.13262993']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

L859-L871

Auteurs

Michael Schuliga (M)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.

Amama Kanwal (A)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.

Jane Read (J)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.

Kaj E C Blokland (KEC)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
Department of Pathology and Medical Biology, Groningen Research Institute of Asthma and COPD and KOLFF Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Janette K Burgess (JK)

Department of Pathology and Medical Biology, Groningen Research Institute of Asthma and COPD and KOLFF Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Cecilia M Prêle (CM)

Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.
Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, University of Western Australia, Nedlands, Western Australia, Australia.

Steven E Mutsaers (SE)

Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.
Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, University of Western Australia, Nedlands, Western Australia, Australia.

Christopher Grainge (C)

Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
John Hunter Hospital, Newcastle, New South Wales, Australia.

Claire Thomson (C)

School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
St Vincent's Hospital, Sydney, New South Wales, Australia.

Allen James (A)

John Hunter Hospital, Newcastle, New South Wales, Australia.

Nathan W Bartlett (NW)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.

Darryl A Knight (DA)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
Priority Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
Providence Health Care Research Institute, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH